Evidence map›Paper›PMID 26904109›Full record

ArticleGastroenterology research and practice2016

Prealbumin/CRP Based Prognostic Score, a New Tool for Predicting Metastasis in Patients with Inoperable Gastric Cancer.

Ali Esfahani, Nima Makhdami, Elnaz Faramarzi, Mohammad Asghari Jafarabadi, Alireza Ostadrahimi, Mousa Ghayour Nahand, Zohreh Ghoreishi

Abstract read
In one paragraph

Article in Gastroenterology research and practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Association of Serum Prealbumin with Angiographic Severity in Patients with Acute Coronary Syndrome.Medical science monitor : international medical journal of experimental and clinical research · 2017
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ali EsfahaniHematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz 5166614711, Iran.
Nima MakhdamiSchool of Medicine, Tabriz University of Medical Sciences, Tabriz 5166614711, Iran.
Elnaz FaramarziLiver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz 5166614711, Iran.
Mohammad Asghari JafarabadiTabriz Health Services Management Research Center and Department of Statistics and Epidemiology, Faculty of Health and Nutrition, Tabriz University of Medical Sciences, Tabriz 5166614711, Iran.
Alireza OstadrahimiNutrition Research Center, Tabriz University of Medical Sciences, Tabriz 5166614711, Iran.
Mousa Ghayour NahandCommon Diseases Risk Factors Management Institute, Tabriz University of Medical Sciences, Tabriz 5166614711, Iran.
Zohreh GhoreishiNutrition Research Center, Tabriz University of Medical Sciences, Tabriz 5166614711, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background. There is a considerable dissimilarity in the survival duration of the patients with gastric cancer. We aimed to assess the systemic inflammatory response (SIR) and nutritional status of these patients before the commencement of chemotherapy to find the appropriate prognostic factors and define a new score for predicting metastasis. Methods. SIR was assessed using Glasgow Prognostic Score (GPS). Then a score was defined as prealbumin/CRP based prognostic score (PCPS) to be compared with GPS for predicting metastasis and nutritional status. Results. 71 patients with gastric cancer were recruited in the study. 87% of patients had malnutrition. There was a statistical difference between those with metastatic (n = 43) and those with nonmetastatic (n = 28) gastric cancer according to levels of prealbumin and CRP; however they were not different regarding patient generated subjective global assessment (PG-SGA) and GPS. The best cut-off value for prealbumin was determined at 0.20 mg/dL and PCPS could predict metastasis with 76.5% sensitivity, 63.6% specificity, and 71.4% accuracy. Metastatic and nonmetastatic gastric cancer patients were different in terms of PCPS (P = 0.005). Conclusion. PCPS has been suggested for predicting metastasis in patients with gastric cancer. Future studies with larger sample size have been warranted.

Identifiers

PMID26904109
PMCPMC4745934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.